IRIS
ZAJA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.525
EU - Europa 3.316
AS - Asia 1.641
SA - Sud America 310
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 2
Totale 17.829
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.460
UA - Ucraina 1.173
SG - Singapore 780
DE - Germania 574
CN - Cina 523
FI - Finlandia 404
IT - Italia 342
BR - Brasile 269
RU - Federazione Russa 266
SE - Svezia 246
IE - Irlanda 185
TR - Turchia 117
KR - Corea 61
CA - Canada 50
GB - Regno Unito 48
HK - Hong Kong 38
IR - Iran 27
VN - Vietnam 26
IN - India 22
BE - Belgio 18
AR - Argentina 16
EU - Europa 14
FR - Francia 13
MA - Marocco 12
CO - Colombia 11
IQ - Iraq 9
MX - Messico 8
CH - Svizzera 7
CZ - Repubblica Ceca 7
AT - Austria 5
BD - Bangladesh 5
ES - Italia 4
NL - Olanda 4
RS - Serbia 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
EC - Ecuador 3
HN - Honduras 3
JO - Giordania 3
KZ - Kazakistan 3
LV - Lettonia 3
PE - Perù 3
PK - Pakistan 3
PL - Polonia 3
PY - Paraguay 3
VE - Venezuela 3
AU - Australia 2
EG - Egitto 2
JP - Giappone 2
KE - Kenya 2
PS - Palestinian Territory 2
RO - Romania 2
AL - Albania 1
AN - Antille olandesi 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PH - Filippine 1
SA - Arabia Saudita 1
TG - Togo 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 17.829
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Woodbridge 1.736
Houston 1.138
Ann Arbor 968
Jacksonville 768
Ashburn 735
Seattle 710
Wilmington 677
Cambridge 616
Chandler 543
Dearborn 503
Singapore 394
Boardman 234
Beijing 229
Princeton 197
Dublin 185
Udine 130
Munich 123
Izmir 111
San Diego 94
Seoul 56
Helsinki 52
Ogden 47
Des Moines 43
Hong Kong 38
Nanjing 37
Norwalk 36
Ottawa 35
New York 32
Kunming 28
Dong Ket 25
Florence 25
Hefei 23
Brussels 18
Los Angeles 18
São Paulo 18
Andover 17
Dallas 16
Guangzhou 16
Saint Petersburg 16
Turku 15
Jinan 14
Santa Clara 14
Shenyang 14
Falls Church 12
Leawood 12
Nanchang 11
San Mateo 11
Bogotá 10
Lappeenranta 10
Shanghai 10
Trieste 10
Ardabil 9
Toronto 9
Belo Horizonte 8
Chengdu 8
Grafing 8
Rio de Janeiro 8
Simi Valley 8
Fremont 7
Nuremberg 7
Venezia 7
Fuzhou 6
Indiana 6
Jyväskylä 6
San Francisco 6
Wuhan 6
Zanjan 6
Zhengzhou 6
Atlanta 5
Augusta 5
Boston 5
Codroipo 5
Hebei 5
Washington 5
Zurich 5
Bari 4
Belgrade 4
Canoas 4
Chongqing 4
Curitiba 4
Jundiaí 4
Milan 4
Monmouth Junction 4
Nanning 4
Ningbo 4
Olomouc 4
Phoenix 4
Porto Alegre 4
Recife 4
Salvador 4
San Jose 4
Santo André 4
Tashkent 4
Amman 3
Ankara 3
Araraquara 3
Arcadia 3
Baghdad 3
Baku 3
Totale 12.895
Salva come PNG Salva come JPEG
Nome #
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 168
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 158
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 156
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 148
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 147
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 145
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 143
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 139
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 139
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 139
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma 137
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 137
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 137
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. 135
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 135
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 134
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 134
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 133
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 132
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 132
Management of immune thrombocytopenia in elderly patients 132
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 131
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 128
More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. 126
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 126
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 124
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 123
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 122
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 122
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 122
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 122
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 120
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 120
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 118
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 117
Peripheral T-cell lymphoma unspecified PTCL-U): a new prognostic model from a retrospective multicentric clinical study 115
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia. 114
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 114
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 114
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 114
Rituximab for the treatment of type II mixed cryoglobulinemia 113
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 113
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 113
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 112
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 112
Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. 111
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 111
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 110
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 109
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 109
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 108
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 108
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. 108
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. 107
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 107
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 107
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. 106
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 106
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 106
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 106
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. 105
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 105
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 105
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients 105
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 104
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 104
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 104
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. 104
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 104
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 103
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 103
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma 102
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 102
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 102
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: A proposal for clinical application 102
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 102
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 101
The role of Rituximab in the therapy of mixed cryoglobulinemia 101
Rituximab-responsive CIDP. 101
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. 100
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 100
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. 99
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 99
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 98
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 97
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. 97
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 97
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 96
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study 96
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 95
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. 95
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 94
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. 94
Temozolomide as salvage treatment in primary brain lymphomas 93
HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. 93
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. 93
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 92
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 92
Persistent CD49d engagement in circulating CLL cells: A role for blood-borne ligands? 92
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 92
Totale 11.397
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.698
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.698
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020413 0 0 0 0 0 0 0 0 0 0 88 325
2020/20212.666 38 344 83 350 73 357 187 328 315 119 300 172
2021/20221.580 57 183 71 109 52 78 100 87 15 261 303 264
2022/20231.323 214 72 20 135 141 398 0 91 171 18 34 29
2023/2024381 60 22 10 14 69 46 22 14 65 25 15 19
2024/20252.288 52 252 154 66 120 168 214 204 342 261 455 0
Totale 18.281